The reverse split is a routine Nasdaq compliance measure. Monitor the effective date and any subsequent Nasdaq listing status updates. The company's fundamentals remain unchanged.
Price Chart
Executive Summary
Cellyan Biotechnology shareholders approved a 1-for-20 reverse share split and related charter amendments at an extraordinary general meeting on September 21, 2026. The consolidation is intended to boost the per-share price to meet Nasdaq listing requirements, but does not change the company's fundamental value or financial position.
Key Facts
- Shareholders approved a 1-for-20 reverse share split of Class A and Class B ordinary shares.
- The consolidation reduces authorized shares from 1,000,000,000 to 50,000,000 ordinary shares.
- The split is effective upon Nasdaq confirmation; no fractional shares will be issued.
- Fifth amended memorandum and articles of association were also approved, conditional on the share consolidation.
- The meeting had 90.29% of total votes present, with near-unanimous approval (360,889,111 for, 6,847 against).
Financial Impact
No financial impact; the reverse split is a mechanical share count adjustment with no change to market capitalization or fundamentals.
Risk Factors
- Reverse splits are often viewed negatively by the market as a sign of financial distress or low share price.
- Post-split price may still fail to maintain Nasdaq's $1.00 minimum bid requirement if the underlying business does not improve.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-102385 |
| Document: 0001213900-26-102385-index-headers.html | 0001213900-26-102385 |
| Document: 0001213900-26-102385-index.html | 0001213900-26-102385 |
| Document: 0001213900-26-102385.txt | 0001213900-26-102385 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.1020 $0.0960 | ▲ +5.88% | ▲ +4.70% | $2.19 (−2047.06%) |
Sep 23, 2026 4w ago | 6-K | $0.1207 $0.1118 | ▼ −7.37% | ▼ −7.92% | $2.19 (+1714.42%) |
Sep 23, 2026 4w ago | 6-K | $0.1192 $0.1207 | ▲ +1.26% | ▲ +1.34% | $2.19 (+1737.25%) |
Jun 25, 2026 17w ago | EFFECT | $0.3710 $0.3610 | ▲ +2.70% | ▲ +1.97% | $2.19 (−490.30%) |
Apr 9, 2026 28w ago | EFFECT | $0.5570 $0.6220 | ▲ +11.67% | ▲ +11.73% | $2.19 (+293.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers